- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
March 1, 2021Amy Churan Named an Insurance Trailblazer by National Law Journal
-
March 1, 2021Firm, Partner Recognized by Managing IP
-
3/1/2021Robins Kaplan Recognized in 2021 World Trademark Review 1000
-
March 6, 2021With Our Voices 2021 Arc Gala
-
March 6, 20211st Annual Tee It Up for the Troops Winter Outing
-
March, 9, 2021The New Frontier of Software License Disputes
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
Winter 2021The Fictional Wealth Disputes That We Took In and Learned From in 2020
-
March 1, 2021Financial Daily Dose 3.1.2021 | Top Story: Walmart Poaches Goldman Bankers in Bid to Bolster Fintech Venture
-
February 26, 2021Financial Daily Dose 2.26.2021 | Top Story: Rising Long-Term Bond Yields Blamed for Jumpy Markets
-
February 25, 2021Financial Daily Dose 2.25.2021 | Top Story: McKinsey Ousts Managing Partner on Heels of Opioid Settlement
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Purdue's Sleep Aid Patents Are Obvious, Judge Rules
March 30, 2015
Law360, New York (March 30, 2015, 3:01 PM ET) -- A New Jersey federal judge on Friday found that Purdue Pharmaceutical Products LP’s three patents for sleep aid Intermezzo are invalid for obviousness, granting a win to Actavis Elizabeth LLC, Novel Laboratories Inc. and others whom Purdue sued over plans to market their own generic versions of the drug.
All Content © 2003‐2015, Portfolio Media, Inc.
Law360
READ FULL ARTICLE Related Professionals
Related Publications
Fourth Quarter
ANDA Approvals
GENERICally Speaking Winter 2021
Fourth Quarter
ANDA Litigation Settlements
GENERICally Speaking Winter 2021
Fourth Quarter
Generic Launches
GENERICally Speaking Winter 2021
Fourth Quarter
New ANDA Cases
GENERICally Speaking Winter 2021
December 21, 2020
Eli Lilly & Co. v. Apotex, Inc.
GENERICally Speaking Winter 2021
Related News
October 12, 2020
June 15, 2020
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.